INTRODUCTION
In the phase 3 MajesTEC-3 study (NCT05083169), teclistamab with daratumumab (Tec-Dara) significantly improved progression-free and overall survival (PFS/OS) versus investigator's choice of standard-of-care daratumumab/pomalidomide/dexamethasone (DPd) or daratumumab/bortezomib/dexamethasone (DVd) in patient...
Larry D. Anderson, S. Nair, Mi-Jun Keng et al.· Advances in Therapy· 0 citations
Multiple myeloma (MM) is a highly fatal disease, particularly in the relapsed-refractory stage, due to drug resistance associated with tumor hypoxia. TPZ, a hypoxia-activated pro-drug, effectively kills hypoxic tumor cells; however, its severe side effects have limited its therapeutic use. This study investigates BCMA-...
M. Maksimos, B. Muz, F. Azab et al.· Journal of Controlled Releas...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.